Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis opens new vaccine research institute
The NVGH’s goal is to address the unmet medical need for vaccines for diseases of the developing world by researching vaccines specifically tailored for developing country needs and
The NVGH’s goal is to address the unmet medical need for vaccines for diseases of the developing world by researching vaccines specifically tailored for developing country needs and
The preliminary results from this prospective study of 30 patients demonstrated that MacuSight’s proprietary formulation of sirolimus (rapamycin) was safe and well-tolerated in all doses tested with two
The physician-sponsored SALVAGE trial, is designed to evaluate the safety and performance of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface and the Spectranetics TURBO-Booster and TURBO elite
Mr. Kondraske joins Omron Healthcare from Pennsylvania based McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, where he was formerly vice president of sales development. Mr. Kondraske
Results show that toremifene citrate 80mg reduced vertebral fractures and met other key endpoints, including bone mineral density, lipid profiles, and gynecomastia. Based on these findings, GTx plans
This placebo controlled, double-blind, Phase IIb study includes multiple doses of orally administered INT131 once daily, and Actos (pioglitazone) as an active comparator. INT131 was the result of
As part of the study, adipose tissue-derived stem and regenerative cells, processed with Cytori’s Celution 600 System, were used to reconstruct breast tissue following partial mastectomy. New data
The delivery of Elekta Neuromag is part of a collaboration contract signed between three parties: Le Commissariat a l’Energie Atomique (CEA), L’Institut National de la Sante et de
The dl5-29 vaccine is an HSV-2 strain from which two genes have been deleted, making the virus incapable of replication or of establishing latent infection. Acambis holds an
PREPS and L-particles were demonstrated to be stable, safe, and well tolerated. The studies also demonstrated that a potent and dose related immune response was generated to the